Key clinical point: MRI is a valuable but not definitive tool for evaluating axial spondyloarthritis (axSpA), agree both the experts and the data.
Major finding: Reflecting the limits of imaging, 28.1% of 131 patients were diagnosed with axSpA by rheumatologists but not radiologists.
Data source: Prospective analysis of consecutive patients.
Disclosures: Dr. Baraliakos reports extensive financial relationships with pharmaceutical companies. Dr. van Gaalen reports none.
Baraliakos X et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):255-6. Abstract OPO344, doi: 10.1136/annrheumdis-2019-eular.5027